Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
2.345
+0.085 (3.76%)
Nov 21, 2024, 12:56 PM EST - Market open
Oramed Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for ORMP.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for ORMP is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 9, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 20, 2024 |
Canaccord Genuity | Canaccord Genuity | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -14.71% | May 17, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 17, 2023 |
Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 12, 2023 |
Financial Forecast
Revenue This Year
n/a
from 1.34M
Revenue Next Year
1.02M
EPS This Year
0.24
from 0.14
Increased by 78.63%
EPS Next Year
-0.08
from 0.24
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | n/a | 2.1M |
Avg | n/a | 1.0M |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | 0.33 | 0.11 |
Avg | 0.24 | -0.08 |
Low | 0.17 | -0.25 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | 137.5% | -57.1% |
Avg | 78.6% | - |
Low | 21.6% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.